Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology

(2021) Nicholas J. Ashton et al.   ACTA NEUROPATHOLOGICA

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers

(2021) N. J. Ashton et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework

(2021) E. E. Wolters et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

(2021) A. Leuzy et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

(2021) Gérard N Bischof et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Alzheimer's disease

(2021) Philip Scheltens et al.   LANCET

Donanemab in Early Alzheimer’s Disease

(2021) Mark A. Mintun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease

(2020) Rik Ossenkoppele et al.   JAMA Neurology

Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography

(2020) Pierre-François Meyer et al.   JAMA Neurology

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

(2020) Nicolas R. Barthélemy et al.   NATURE MEDICINE

The implications of different approaches to define AT(N) in Alzheimer disease

(2020) Niklas Mattsson-Carlgren et al.   NEUROLOGY

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

(2020) Shorena Janelidze et al.   Nature Communications

Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals

(2020) Reisa A. Sperling et al.   JAMA Neurology

Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes

(2020) Adam S. Fleisher et al.   JAMA Neurology

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders

(2020) Antoine Leuzy et al.   JAMA Neurology

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   Science Advances

18F-MK-6240 PET for early and late detection of neurofibrillary tangles

(2020) Tharick A Pascoal et al.   BRAIN

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

(2020) Sebastian Palmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Synergy between amyloid-β and tau in Alzheimer’s disease

(2020) Marc Aurel Busche et al.   NATURE NEUROSCIENCE

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   BRAIN

Association of amyloid-β CSF/PET discordance and tau load five years later

(2020) Juhan Reimand et al.   NEUROLOGY

Amyloid‐ β PET and CSF in an autopsy‐confirmed cohort

(2020) Juhan Reimand et al.   Annals of Clinical and Translational Neurology

The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects

(2020) Ruben Smith et al.   BRAIN

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum

(2020) Alexis Moscoso et al.   BRAIN

The impact of demographic, clinical, genetic, and imaging variables on tau PET status

(2020) Rik Ossenkoppele et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity

(2020) Arianna Sala et al.   MOLECULAR PSYCHIATRY

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

(2020) Shorena Janelidze et al.   JAMA Neurology

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease

(2019) Rik Ossenkoppele et al.   NEUROLOGY

A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia

(2019) Michael J Pontecorvo et al.   BRAIN

Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid

(2019) Valeria Lifke et al.   CLINICAL BIOCHEMISTRY

The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes

(2019) Clifford R Jack et al.   BRAIN

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences

(2019) Arno de Wilde et al.   Alzheimers Research & Therapy

Tau-positron emission tomography correlates with neuropathology findings

(2019) Val J. Lowe et al.   Alzheimers & Dementia

Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography

(2018) Michelle M. Mielke et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Longitudinal tau PET in ageing and Alzheimer’s disease

(2018) Clifford R Jack et al.   BRAIN

Evaluation of18F-RO-948 (18F-RO6958948) for quantitative assessment of tau accumulation in the human brain with positron emission tomography

(2018) Hiroto Kuwabara et al.   JOURNAL OF NUCLEAR MEDICINE

Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2017) Jeff Sevigny et al.   NATURE

Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease

(2017) Anne Maass et al.   NEUROIMAGE

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity

(2017) Sebastian Palmqvist et al.   Nature Communications

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

(2017) Susanne Ostrowitzki et al.   Alzheimers Research & Therapy

In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum

(2016) Hanna Cho et al.   ANNALS OF NEUROLOGY

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

(2016) Sebastian Palmqvist et al.   BRAIN

Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles

(2016) E. D. Hostetler et al.   JOURNAL OF NUCLEAR MEDICINE

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

(2016) Clifford R. Jack et al.   NEUROLOGY

PET Imaging of Tau Deposition in the Aging Human Brain

(2016) Michael Schöll et al.   NEURON

The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET

(2015) William E. Klunk et al.   Alzheimers & Dementia

Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative

(2015) Michael W. Weiner et al.   Alzheimers & Dementia

Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue

(2015) Marta Marquié et al.   ANNALS OF NEUROLOGY

Tau positron emission tomographic imaging in aging and early Alzheimer disease

(2015) Keith A. Johnson et al.   ANNALS OF NEUROLOGY

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

(2014) Niklas Mattsson et al.   BRAIN

The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease

(2014) Tara L. Spires-Jones et al.   NEURON

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

[18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease

(2013) Chun-Fang Xia et al.   Alzheimers & Dementia

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid

(2013) Susan M. Landau et al.   ANNALS OF NEUROLOGY

Biomarker Modeling of Alzheimer’s Disease

(2013) Clifford R. Jack et al.   NEURON

Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections

(2012) Jan Jessen Krut et al.   JOURNAL OF NEUROLOGY

Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

(2012) Peter T. Nelson et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Soluble amyloid  -protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration

(2011) M. Jin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

Cognitive and Cortical Plasticity Deficits Correlate with Altered Amyloid-β CSF Levels in Multiple Sclerosis

(2010) Francesco Mori et al.   NEUROPSYCHOPHARMACOLOGY

Age, Neuropathology, and Dementia

(2009) George M. Savva et al.   NEW ENGLAND JOURNAL OF MEDICINE